SCHEMBL20007716

SCHEMBL20007716

CCc1ccc(N(C)C(=O)[C@@H](N)CCc2cc(F)cc(F)c2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PER2 O15055 1/20 0.32
CRY1 Q16526 1/20 0.32
CRY2 Q49AN0 1/20 0.32
MAOB P27338 1/20 0.32
ALDH1A1 P00352 2/20 0.32
LMNA P02545 2/20 0.32
GRIK1 P39086 1/20 0.32
GRIA1 P42261 1/20 0.32
GRIA2 P42262 1/20 0.32
GRIA3 P42263 1/20 0.32
GRIA4 P48058 1/20 0.32
GRIK2 Q13002 1/20 0.32
GRIK3 Q13003 1/20 0.32
CIT O14578 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
MLYCD O95822 1/20 0.32
AAK1 Q2M2I8 1/20 0.31
GAA P10253 2/20 0.31
KIF11 P52732 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18180281 0.87 CIT (0.39) PER2CRY1CRY2MAOBALDH1A1
SCHEMBL19969131 0.85 NR1H4 (0.40) ALDH1A1LMNAMLYCDKIF11MEN1
SCHEMBL19962121 0.80 CIT (0.38) PER2CRY1CRY2MAOBALDH1A1
SCHEMBL20007415 0.80 HSP90AA1 (0.40)
SCHEMBL21992337 0.78 MAOB (0.39) PER2CRY1CRY2MAOBALDH1A1
SCHEMBL20427707 0.77 PDE10A (0.34) AAK1
SCHEMBL20007412 0.76 CTSK (0.41)
SCHEMBL19999801 0.76 CIT (0.41) CRY1CRY2MAOBALDH1A1LMNA
SCHEMBL18317595 0.74 CIT (0.39) ALDH1A1LMNACITMEN1KMT2A
SCHEMBL18180401 0.74 CIT (0.39) ALDH1A1LMNACITMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10221129-B2 Inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2019-03-05 US disclosed
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221129-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR2E, POLR2H PER2 3359/4885CRY1 4345/4885CRY2 4658/4885
US-20180086697-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H PER2 3359/4885CRY1 4345/4885CRY2 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.